Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
PRNewsWire
·
2026-05-28
·
via The Tech Buzz - Press Releases
SHANGHAI and HONG KONG, May 27, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.H…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。